The Goodwin Technology team advised Clairity, Inc., an AI-driven precision health company, on its $43 million Series B financing. The funds will support the commercialization of Clairity Breast and the continued development of additional AI-enabled diagnostic solutions for cardiovascular and breast health.
Clairity is an AI-powered precision health company transforming medical imaging into a predictive tool for early risk assessment. Its flagship product, Clairity Breast, is the first FDA-cleared platform to estimate a woman’s five-year breast cancer risk directly from a routine mammogram. By shifting care from detection to prevention, Clairity empowers health systems, radiologists, and women to act earlier, save lives, and lower the overall cost of cancer care.
The Goodwin team was led by Bill Schnoor, Matt Reardon, Taylor Harrison, and Matt Salit.
For more information, please read the press release.